Home › Compound Library › Valsartan (Diovan)

Valsartan (Diovan)

ARBprescriptionoral · inferred

Angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors. Used for hypertension, heart failure, and post-MI. Unlike ACE inhibitors, does not cause cough or angioedema (no effect on bradykinin). 25% oral bioavailability, unaffected by CYP metabolism, primarily eliminated unchanged in bile/feces. Available in combination with HCTZ, amlodipine, and sacubitril (Entresto for HF).

Projected serum levels — 80 mg, once daily

Valsartan (Diovan)
Valsartan (Diovan) modeled serum levels, 80 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 80 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 15.3 mg, trough ≈ 1.6 mg body load. Population-based estimate over 15 days for a 80 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
ARB
Route modeled
Oral
Model confidence
inferred
Half-life
6 h
Common dose
80 mg
Suggested maximum
320 mg/day
Reference dose range
40–320 mg (single dose)
Suggested cadence
once daily
Validated against
80 mg oral — Cmax 1.8 mg/L at 3 h

Documented interactions

  • danger
    Carbamazepine (Tegretol) + Valsartan (Diovan) CYP induction

    Carbamazepine (Tegretol) inducer of CYP2C9 predicted to change Valsartan (Diovan) AUC by ~0.40x

  • danger
    CBD (Cannabidiol) + Valsartan (Diovan) CYP inhibition

    CBD (Cannabidiol) reversible_inhibitor of CYP2C9 predicted to change Valsartan (Diovan) AUC by ~3.33x

  • danger
    Fluconazole + Valsartan (Diovan) CYP inhibition

    Fluconazole reversible_inhibitor of CYP2C9 predicted to change Valsartan (Diovan) AUC by ~3.33x

  • danger
    Fluvoxamine (Luvox) + Valsartan (Diovan) CYP inhibition

    Fluvoxamine (Luvox) reversible_inhibitor of CYP2C9 predicted to change Valsartan (Diovan) AUC by ~3.33x

  • danger
    Metronidazole (Flagyl) + Valsartan (Diovan) CYP inhibition

    Metronidazole (Flagyl) reversible_inhibitor of CYP2C9 predicted to change Valsartan (Diovan) AUC by ~3.33x

  • danger
    Milk Thistle (Silymarin / Silybin) + Valsartan (Diovan) CYP inhibition

    Milk Thistle (Silymarin / Silybin) reversible_inhibitor of CYP2C9 predicted to change Valsartan (Diovan) AUC by ~3.33x

Serum checks 27 modeled interaction pairings for valsartan (diovan) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Valsartan, captopril, or both in myocardial infarction complicated by heart failure (VALIANT trial) Pfeffer MA et al. · New England Journal of Medicine, 2003 DOI

    Landmark RCT (14,703 patients) demonstrating valsartan was as effective as captopril for reducing mortality after MI complicated by heart failure, establishing ARBs as valid ACE inhibitor alternatives.

  2. A randomized trial of valsartan in chronic heart failure (Val-HeFT) Cohn JN, Tognoni G · New England Journal of Medicine, 2001 DOI

    Large RCT (5010 patients) showing valsartan added to standard HF therapy reduced composite morbidity/mortality by 13%, driven primarily by 24% reduction in heart failure hospitalizations.

2 published studies referenced in the app, each with a plain-language summary.